Publication Date

Spring 5-5-2022

Document Type


First Advisor

Zhou, Haiming

Degree Name

B.S. (Bachelor of Science)


Department of Statistics and Actuarial Science


This project is focused on the recovery rates of patients diagnosed with COVID-19 after different clinical trial drug treatments. Data for the clinical trial studied was obtained from the National Institute of Allergy and Infectious Diseases for the primary purpose of a survival analysis on patient time to recovery under a placebo and therapeutic drug treatment. Specifically, patients in this clinical trial were randomly selected to receive remdesivir, an antiviral drug, in combination with a placebo or baricitinib, a janus kinase inhibitor drug. Cox PH models were used to identify how the different treatment drugs affect time to recovery and time to death, along with what other patient factors may have an association with both time to recovery and time to death. It was found that the combination of remdesivir and baricitinib yields a faster recovery time than using remdesivir alone for treatment. Research on clinical trial drugs is vital for discovering possible treatments for widespread diseases such as the COVID-19 pandemic.